Satellos Bioscience Inc. Stock
Stocks
MSCL
CA80401L8033
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Toronto S.E.
03:59:41 24/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 9.130 CAD | +0.11% |
|
-1.30% | +15.28% |
| 10-05 | Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO | MT |
| 10-05 | Satellos Bioscience Receives US Patent for Forazapadin | MT |
| Market Cap | 138M 124M 114M 104M 194M 13.15B 197M 1.37B 544M 6.89B 520M 509M 21.72B | P/E 2026 * |
-3.1x | P/E 2027 * | -4.1x |
|---|---|---|---|---|---|
| Enterprise Value | 36.89M 32.95M 30.44M 27.58M 51.6M 3.5B 52.46M 366M 145M 1.83B 138M 136M 5.79B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.63% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| MSCL | Delayed | |
Nasdaq
| MSLE | Delayed | |
|
Börse Stuttgart
| 0IT | Delayed | |
|
CBOE
| MSLE | Real-time | |
|
Deutsche Boerse AG
| 0IT | Delayed | |
|
Tradegate
| 0IT | Real-time |
| 1 day | +0.11% | ||
| 1 week | -1.30% | ||
| Current month | -24.48% | ||
| 1 month | -24.98% | ||
| 3 months | -33.31% | ||
| 6 months | -3.89% | ||
| Current year | +15.28% |
| 1 week | 9.02 |  | 9.84 |
| 1 month | 9.02 | | 12.64 |
| Current year | 7.67 | | 18.98 |
| 1 year | 7.56 | | 18.98 |
| 3 years | 3.48 | | 18.98 |
| 5 years | 2.58 | | 18.98 |
| 10 years | 2.58 | | 22.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Gleeson
CEO | Chief Executive Officer | 70 | 01/03/2018 |
Michael Rudnicki
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2018 |
| Director of Finance/CFO | - | 01/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff MacKay
CHM | Chairman | 59 | 01/07/2018 |
Brian Bloom
BRD | Director/Board Member | 50 | 01/03/2018 |
Frank Gleeson
BRD | Director/Board Member | 70 | 01/07/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/8/26 | Option | Director | 10,608 | 0.0509% | ||
| 18/8/26 | Option | Director | 10,608 | 0.0509% | ||
| 18/8/26 | Option | Director | 10,608 | 0.0509% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.11% | -1.30% | +2.82% | +95.09% | 138M | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.78B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.49B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.98B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 42.94B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.67B | |
| +1.19% | -4.98% | +29.01% | -0.65% | 23.97B | |
| Average | +0.26% | +2.04% | +44.84% | +151.30% | 38.33B | |
| Weighted average by Cap. | +0.39% | +2.73% | +47.56% | +158.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -49.92M -44.58M -41.18M -37.32M -69.82M -4.74B -70.98M -496M -196M -2.48B -187M -183M -7.83B | -65.51M -58.5M -54.04M -48.97M -91.62M -6.22B -93.14M -650M -257M -3.26B -246M -241M -10.27B |
| Net Debt | -102M -90.73M -83.82M -75.96M -142M -9.64B -144M -1.01B -399M -5.05B -381M -373M -15.93B | -119M -106M -98.17M -88.96M -166M -11.3B -169M -1.18B -468M -5.92B -447M -437M -18.66B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | CA$9.130 | +0.11% | 7,208 |
| 22/10/26 | CA$9.120 | -4.20% | 17,660 |
| 21/10/26 | CA$9.520 | -1.96% | 4,855 |
| 20/10/26 | CA$9.710 | +5.77% | 9,250 |
| 19/10/26 | CA$9.180 | -0.76% | 5,746 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MSCL Stock
Select your edition
All financial news and data tailored to specific country editions
